^
BIOMARKER:

KRAS exon 3 mutation

i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
27d
RAS mutation appears infrequent, and it is not associated with any specific histological phenotype of glioma.
Journal
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • HRAS (Harvey rat sarcoma viral oncogene homolog) • RB1 (RB Transcriptional Corepressor 1) • TERT (Telomerase Reverse Transcriptase)
|
KRAS mutation • BRAF mutation • NRAS mutation • IDH1 mutation • KRAS exon 3 mutation
2ms
Among KRAS exon 2 mutated patients, codon 13 mutations predict worse prognosis than codon 12 mutations. Mutations of different KRAS exons should be analyzed separately.
Clinical • Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS exon 2 mutation • KRAS exon 3 mutation • KRAS exon 4 mutation
3ms
Additional analysis of RAS and BRAF mutations could contribute to the selection of patients who are likely to benefit from third-line EGFR inhibitors, regardless of primary tumor location.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • EGFR mutation • BRAF V600 • PIK3CA mutation • KRAS exon 2 mutation • KRAS exon 3 mutation
|
irinotecan
4ms
P2, N=35, Recruiting, Criterium, Inc. | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
Clinical • Trial completion date • Trial primary completion date
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS exon 2 mutation • KRAS exon 3 mutation • KRAS exon 4 mutation
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
4ms
P3, N=474, Recruiting, GERCOR - Multidisciplinary Oncology Cooperative Group | Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Dec 2019 --> Jun 2021
Clinical • Trial completion date • Trial primary completion date
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
NRAS mutation • KRAS exon 3 mutation • KRAS exon 4 mutation
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
8ms
P2, N=34, Active, not recruiting, Grupo Espanol Multidisciplinario del Cancer Digestivo | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2020 --> Oct 2020
Clinical • Enrollment closed • Trial primary completion date • Combination therapy
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
KRAS exon 3 mutation • KRAS exon 4 mutation • BRAF exon 15 mutation
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium
10ms
Clinical • Enrollment open • Preclinical • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G13 • KRAS G12 • KRAS exon 2 mutation • KRAS Q61 • KRAS A146 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation
|
irinotecan • BI 1701963
11ms
Clinical • New P1 trial • Preclinical • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G13 • KRAS G12 • KRAS exon 2 mutation • KRAS Q61 • KRAS A146 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation
|
irinotecan • BI 1701963
1year
P1, N=7, Completed, NYU Langone Health | Recruiting --> Completed | N=32 --> 7 | Trial completion date: Sep 2020 --> Mar 2020 | Trial primary completion date: Mar 2019 --> Mar 2020
Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF mutation • KRAS exon 2 mutation • KRAS exon 3 mutation • KRAS exon 4 mutation • BRAF exon 15 mutation
|
adavosertib (AZD1775) • irinotecan
1year
P2, N=47, Recruiting, Grupo Espanol Multidisciplinario del Cancer Digestivo | Trial completion date: Apr 2022 --> Oct 2022 | Trial primary completion date: Jan 2022 --> Jul 2020
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
KRAS exon 3 mutation • KRAS exon 4 mutation • BRAF exon 15 mutation
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium
over1year
P2, N=35, Recruiting, Criterium, Inc. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS exon 2 mutation • KRAS exon 3 mutation • KRAS exon 4 mutation
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium